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Animals using toxic peptides and proteins for predation or defense typically depend on
specialized morphological structures, like fangs, spines, or a stinger, for effective intoxication.
Here we show that amphibian poisons instead incorporate their own molecular system for
toxin delivery to attacking predators. Skin-secreted peptides, generally considered part of the
amphibian immune system, permeabilize oral epithelial tissue and enable fast access of
cosecreted toxins to the predator’s bloodstream and organs. This absorption-enhancing
system exists in at least three distantly related frog lineages and is likely to be a widespread
adaptation, determining the outcome of predator–prey encounters in hundreds of species.
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When a poisonous or venomous animal is attacked by apredator, it usually has little time to deploy its toxinsand induce a response in the aggressor to avoid being
killed (Fig. 1a). To achieve this, animals may produce toxins with
immediate local effects, like pain or distastefulness, or molecules
with systemic effects that rely on fast inﬁltration into a predator’s
body1. In the absence of structures that create a wound to inject
toxins, fast delivery is typically only possible for small molecules
(<300 Da) that are easily absorbed through oral epithelia, like
cyanides, alkaloids, or steroids1,2. Many frog species however,
secrete much larger molecules with systemic targets, like peptides
(typically 0.5–2 kDa) and in some cases even small proteins
(4–8 kDa)3–7. These toxins generally resemble vertebrate
hormones or neuropeptides and undergo posttranslational
modiﬁcations that increase their lifespan in a predator’s blood-
stream or enhance their afﬁnity to a target receptor8–10. Upon
receptor binding, these toxins essentially simulate an overdose of a
predator’s hormone or neuropeptide, resulting in a range of adverse
effects, including nausea, hypotension, and hyperalgesia3,7,9,10.
The large size and physicochemical properties of peptides
renders them unsuitable for fast epithelial absorption1,2,11–13. The
poisons of many frogs thereby seem to defy the constraints
of passive toxin uptake, and hint at a mechanism that allows
systemic delivery fast enough to evade predation. Besides toxins,
many frogs secrete antimicrobial peptides (AMPs), capable of
killing a broad range of microorganisms through cell lysis14,15.
Since their ﬁrst characterization in the late 1980s, AMPs have
been generally considered a component of the amphibian innate
immune system, and investigated primarily in light of their
potency against clinically important pathogens3,14–18. Recently
however, an alternative role in antipredator defense has been
suggested, and it was predicted that AMPs, through a similar
cytolytic activity, could permeabilize a predator’s epithelial tissue
to facilitate toxin delivery7. Proof for this hypothesis would
highlight a long-overlooked function of amphibian AMPs besides
innate immunity, and drastically alter our perception of how they
contribute to an amphibian’s survival. Here we report on a series
of in vitro and in vivo experiments that provide compelling
evidence for an antipredatory role of AMPs. Our results complete
the picture of a toxin delivery system as sophisticated as that of
many venomous animals, be it molecular rather that morpholo-
gical in nature.
Results
AMP-enhanced transepithelial passage of a peptide toxin. As
the main model for our study, we used a peptide pair composed
of the systemic toxin caerulein, and the AMP caerulein precursor
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Fig. 1 A frog antimicrobial peptide promotes the transepithelial passage of a cosecreted toxin. a Litoria caerulea (an Australian tree frog) attacked by the
snake Dendrelaphis punctulatus. Note the defensive skin secretion (black arrow), known to contain toxins (including caerulein) and AMPs (photograph taken
by Jannie Smit). b Amino-acid sequences of the X. laevis skin toxin caerulein (Cae) and its cosecreted antimicrobial peptide, caerulein precursor fragment
(CPF). c Lactate dehydrogenase (LDH) leakage indicates cell damage in a Caco-2 epithelial model exposed to a mixture of caerulein and CPF but not to
caerulein alone (n= 7; 100% corresponds to the LDH leakage caused by complete cell lysis as induced by Triton-X). d Co-administration of CPF induces
a rapid prolonged drop in transepithelial electrical resistance (TEER) of Caco-2 monolayers (n= 9, one-way ANOVA, F(4, 40)= 1345.6, p< 0.0005).
e Caerulein alone does not damage Caco-2 monolayers, but co-administration of CPF results in intercellular ruptures (white arrow), as revealed by
scanning electron microscopy. Scale bars represent 100 μm. f Co-administration of CPF at the apical side leads to higher caerulein levels after 60min at the
basolateral side, indicating enhanced transepithelial transport across Caco-2 monolayers (n= 9, t-test, t(8.2)= −7.3, p< 0.0005) and an oral multilayer
model (n= 8, t-tests, t(9.1)= −9.6, p< 0.0005). All data are mean± s.e.m., error bars not shown when covered by data symbols
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fragment-3 (CPF), both of which are key constituents of the skin
secretion of the frog Xenopus laevis18–20 (Fig. 1b). Caerulein is
a potent ligand of cholecystokinin receptors expressed in the
vertebrate intestine, pancreas, and brain9, and at sufﬁciently high
concentrations, may induce nausea, hypotension, intestinal
cramps, vomiting, and diarrhea9,21,22. Even in the intestine, the
target receptors are only accessible by means of epithelial
absorption, since they are expressed at the basolateral side (inside
the tissue) of the intestinal wall. Because caerulein is a widespread
toxin in frogs3,7,9 with a long half-life in the bloodstream (up to
45 min)8,23, this peptide makes a suitable model to investigate
mechanisms of toxin delivery.
The absence of lactate dehydrogenese (LDH) leakage after
applying caerulein (100 μM) to epithelial cell cultures indicate
that the toxin is incapable to damage epithelial cells by itself
(Fig. 1c). However, co-administration of caerulein and CPF,
resembling the natural condition of the frog’s skin secretion,
resulted in dose-dependent LDH leakage within 5 min indicating
rapid and large-scale damage to cell membranes. Application of
CPF alone produced a similar level of LDH leakage, conﬁrming
that this peptide, besides lysing bacteria, is capable to perforate
epithelial cells (Supplementary Fig. 1a). Accordingly, administra-
tion of CPF and caerulein combined, or CPF alone, strongly
reduced epithelial barrier integrity as measured by transepithelial
electrical resistance (TEER) across cell monolayers (Fig. 1d;
Supplementary Fig. 1b). While application of caerulein alone
caused no apparent loss of TEER, exposure to CPF caused an
immediate, dose-dependent drop in epithelial barrier integrity. At
100 μM caerulein + 100 μM CPF, TEER dropped to 10%± 2.5 of
the original value within 5 min. The loss of epithelial integrity is
explained by damage to the monolayer that exceeds the mere lysis
of individual cells (Fig. 1e). The presence of CPF caused abundant
intercellular ruptures in the monolayer, indicating that adherent
cells were detached, possibly as a consequence of CPF-induced
cytolysis. This damage allowed the passage of caerulein across cell
monolayers as conﬁrmed by enzyme-linked immunosorbent
assay (ELISA; Fig. 1f). When caerulein alone (100 μM or 20 nmol)
was applied at the apical side of the monolayer (representing the
oral cavity), ~ 0.3–1.0% (0.06–0.20 nmol) of the toxin had passed
to the basolateral side (representing a predator’s tissue and blood)
after 60 min. When CPF was co-administered (at the same
concentration), transepithelial passage of caerulein rose to
2.3–6.8% (0.45–1.36 nmol) of the applied dose, representing a
near sevenfold increase on average in the rate of transepithelial
passage. Similarly, a nearly ﬁvefold increase in toxin passage was
observed when an oral epithelial model composed of 8–11 stacked
cell layers was used, showing the capacity of the AMP to enhance
peptide passage through thicker, more complex epithelia (Fig. 1f).
Although for both epithelial models, the percentage of transferred
caerulein remains relatively low, the signiﬁcant increase caused by
the AMP is likely to provide a major advantage to a frog under
attack, provided that its skin secretion contains a high
concentration of the toxin (see next section).
AMP-enhanced intoxication of a live predator. Our in vitro
experiments provide a strong indication that frog AMPs indeed
enhance the transepithelial passage of cosecreted toxins. To test
whether this pattern holds in a live model predator, we quantiﬁed
radiolabeled caerulein (Supplementary Fig. 2) absorbed by
snakes until 30 min after oral administration in the presence vs.
absence of CPF (Fig. 2a). This time window corresponds well with
reported times required for snakes and several other predators
to subdue and ingest frogs24,25. Despite the long half-life
of caerulein, radioactivity measurements across such period
may increasingly overestimate the amount of intact toxin in a
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Fig. 2 AMP co-administration accelerates toxin absorption in a live predator. a Investigated organs and tissues in the model predator Thamnophis eques;
numbers are cross-referenced in b and c. b Caerulein (Cae) blood concentrations reach higher levels (left graph), which leads to higher systemic exposure
(right graph) when orally co-administered with CPF at 1 mM (n= 3, linear mixed model, X2 (1)= 11.4, p< 0.001). c Caerulein levels in organs are higher in
snakes when co-administered with CPF after 30min (n= 3, linear mixed model, X2 (1)= 4.7, p= 0.029). Symbols represent individual data values. Linear
mixed models are explained in the Methods section
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predator’s body. Nevertheless, the radiolabeled peptide provides a
useful tool to quantify and compare the efﬁciency of epithelial
absorption as the ﬁrst step of predator intoxication.
In a ﬁrst in vivo experiment, we administered both peptides at
1 mM (50 nmol in 50 µl buffer solution). This is a biologically
realistic concentration for frog skin secretions according to
reported estimates for AMPs26–28 and ELISA estimates for
caerulein (0.12–4.27 mg caerulein per frog, corresponding to
0.088–3.16 μmol, or 1.0–7.5 mM in the skin secretions; Supple-
mentary Fig. 3). Monitoring of caerulein levels in the snakes’
blood after oral administration revealed a variable but strong
effect of the AMP on toxin absorption (Fig. 2b). In the absence of
CPF, caerulein blood levels remain low (below 8 pmol/g blood)
throughout the experiment, but in the presence of CPF, they
reach concentrations of 19–87 pmol/g blood after 10 min and
26–133 pmol/g blood after 30 min. Taking into account that a
snake’s blood takes 5–8% of its body weight (BW)29, these blood
levels correspond to 0.96–4.36 pmol/g BW after 10 min and
1.28–6.66 pmol/g BW after 30 min. The dose at which caerulein
causes adverse effects in snakes is unknown, but the levels
observed here largely exceed intravenously injected doses that in
previous experiments caused severe sickness in other vertebrates
(1 μg/kg BW, corresponding to 0.74 pmol/g BW)9,21,22. Over
30 min, systemic exposure to the toxin (area under the curve
(AUC) derived from repeated blood measurements) ranged up to
13 times higher in the presence of CPF (Fig. 2b), and average
caerulein levels in various organs ranged between 1.3 and 10.4
times higher (Fig. 2a, c). The higher caerulein levels in all organs
suggest that the AMP did not direct the toxin to its speciﬁc target
organs (intestine, pancreas, and perhaps the brain), but instead
facilitated dispersal of the toxin throughout the predator’s system
by accelerating absorption. A second in vivo experiment, based
on the oral administration of 10-fold lower peptide concentra-
tions (100 µM) conﬁrmed that the effect of the AMP is still
apparent at the concentration used in our in vitro experiments. In
the presence of CPF, estimated exposure was up to three times
higher and average organ concentrations after 30 min ranged
between 1.7 and 3.4 times higher (Supplementary Fig. 4).
A widespread role of frog AMPs in toxin absorption. AMPs
have been characterized in hundreds of frog species, and have
been postulated to represent independent evolutionary origins in
distantly related frog lineages30. Besides CPF and related peptides
in species of the family Pipidae18–20, AMPs are particularly
prominent in the skin secretions of discoglossoid and neoba-
trachian frogs, in which they, too, co-occur with peptide toxins
(Fig. 3a). To investigate whether absorption-enhancing capacity is
a shared trait of AMPs from phylogenetically distant frog linea-
ges, we conducted experiments on two additional peptide pairs
(Fig. 3b): The toxin bombesin (Bom) and the AMP bombinin-like
peptide 1 (BLP) from the skin of the oriental ﬁre-bellied toad
Bombina orientalis (Discoglossoidea: Bombinatoridae); and the
toxin dermorphin and the AMP dermaseptin-S1 (Drs) from the
skin of the waxy tree frog Phyllomedusa sauvagii (Neobatrachia:
Hylidae). The toxin bombesin is a potent ligand of neuromedin
receptors expressed on smooth muscle cells surrounding the gut
and blood vessels, which causes hypotension and smooth muscle
spasms31–33. Dermorphin causes sedation and shock upon
binding its target opioid receptors in the nervous system10,34,35.
Like caerulein, both toxins require access to the bloodstream to
induce these effects, and have structural adaptations to extend
their half-lives in the bloodstream and tissues34,36.
Similar to caerulein, neither bombesin nor dermorphin
induced any damage to epithelial tissue by themselves (Fig. 3c;
Supplementary Fig. 5a). In contrast, co-administration of their
respective AMPs, or application of the AMPs alone resulted in
rapid and severe cell leakage and loss of epithelial integrity
(Fig. 3d; Supplementary Fig. 5b). BLP and Drs enhanced the
transepithelial passage of their cosecreted peptide toxins by ~ 4.5
and 20 times, respectively (Fig. 3e). These results suggest that
absorption-enhancing activity is likely to be a prevalent feature of
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Fig. 3 The role of frog AMPs in toxin absorption in other frog species. a Representatives of three major frog lineages cosecrete peptide toxins and AMPs.
b Amino-acid sequences of the Bombina ortienalis toxin bombesin (Bom) and AMP bombinin-like peptide 1 (BLP), and of the Phyllomedusa sauvagii toxin
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mixtures, but not to the toxins alone (n= 6–7; 100% corresponds to the LDH leakage caused by complete cell lysis as induced by Triton-X). d BLP and Drs
induce a dose-dependent rapid drop in transepithelial electrical resistance (TEER) of Caco-2 monolayers (n= 9, one-way ANOVA, FDRS(4,40)= 1284,
FBLP(4,40)= 2054.1, p< 0.0005). e Co-administration of BLP and Drs at the apical side of Caco-2 monolayers leads to higher toxin levels after 60min
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anuran AMPs, contributing to predator intoxication by a wide
range of species.
Discussion
Most research on amphibian skin-secreted peptides has a
predominantly pharmacological scope, aiming to characterize
their physiological effects, not their natural mode of delivery.
By investigating the process of intoxication “from a frog’s
perspective”, our study has two major implications.
First, we provide evidence for a function of amphibian AMPs
outside the immune system. Due to their pore-forming activity
and expression in the skin, AMPs are inclined to serve a dual role,
in innate immunity as well as antipredator defense. In fact,
besides enhancing the absorption of cosecreted toxins, the cyto-
toxic activity of amphibian AMPs may cause irritation or pain on
oral mucosa, thereby providing a secondary and fast-acting effect
on some predators. The broad-spectrum antimicrobial activity of
many amphibian AMPs continues to fuel the perception that they
are promising lead compounds for the development of new
antibiotics3,18,37,38. The present evidence however, implies that
pharmacological studies seeking to optimize the therapeutic
potential of frog AMPs should take their potential damaging
effect on epithelial tissue into account.
Second, our results show that toxin systems relying on epi-
thelial absorption may be more complex than currently perceived,
involving multiple factors that together maximize the effective-
ness of intoxication. At least in peptide-secreting frogs, epithelial
permeabilization is likely to be a decisive step, reducing the time
for toxins to reach an adverse effect in the predator. The secretion
of large amounts of toxin additionally increases the probability
that effective toxin levels are attained in the predator’s system
even if only a small percentage of the toxin is absorbed. Similar to
the large amounts of caerulein in X. laevis skin secretion found
here, quantities ranging up to milligrams have been reported for
toxins in the skin secretion of other frog species, including
caerulein in Litoria caerulea (Fig. 1a), and bombesin and der-
morphin in Bombina and Phyllomedusa species, respec-
tively10,39,40. With molecular weights of, respectively, 802.9,
1352.4, and 1619.9 Da, dermorphin, caerulein, and bombesin lie
within the typical size range of anuran peptide toxins. A
few toxins however, like anntoxin in Hyla annectans, sauvagine in
P. sauvagii, or prokineticins in Bombina are much larger
(4–8 kDa)4–6. The question remains whether toxins of this size
would also beneﬁt from AMP-enhanced absorption. The degree
by which epithelial transfer was enhanced in our in vitro
experiments seemed inversely correlated to the toxins’ molecular
weights, which may indeed indicate that a peptide’s size affects an
AMP’s capacity to mediate its transepithelial uptake.
Absorption enhancement is likely to be effective against
predators whose limited prey-handling skills require considerable
time to subdue their prey, and/or swallow their prey whole
(e.g., predatory ﬁsh, lizards, and large amphibians). In addition, it
may act in concert with ingestion-delaying behavior such as
struggling or inﬂating. For various snake species, recorded times
between capture and ingestion of amphibians averaged
15–35 min24 and in some cases ranged up to 50 min25. Similarly,
amphibians have been documented to survive up to 20 min in the
gastrointestinal tract of bullfrogs and ﬁsh after being swallowed
completely25. If in the latter case sickness is induced before
the frog dies, it might be regurgitated and escape. Even in
predators whose preying technique precludes survival of the
frog (e.g., involving severe trauma before ingestion), enhanced
toxin absorption could still adversely affect the predator and be
beneﬁcial to the remaining frog population, possibly aided by
predator learning25,41,42.
We anticipate that other animals administering their toxins
through absorption may use similar mechanisms of tissue
permeabilization. The defense secretions of several whipscorpion
species (order Thelyphonida), for example, contain caprylic acid,
which, besides increasing the effective contact area of the sprayed
secretion, enhances the penetration of cosecreted acetic acid
through arthropod cuticle43. Examples involving toxic peptides or
proteins with systemic targets may include salamanders44,
nemertean worms45, and cone snails releasing insulin-based
secretions46. Moreover, the venoms of animals relying on active
injection like biting or stinging (spiders, insects, and cnidarians)
often include cytolytic agents, which may further improve toxin
spreading47–49. As such, our ﬁndings call for a rethinking of the
textbook distinction between poisonous animals (relying on
absorption of their toxins) and venomous ones (creating a wound
to guide toxins into the victim)1,2,50,51. Well-known toxin deliv-
ery systems range from macroscopic structures (like snake fangs
or insect stingers) down to cellular adaptations (nematocysts in
cnidarians). The molecular delivery system identiﬁed here
represents an extension down the biological scale, and show that
toxin delivery can be mediated at any suborganismal level.
Methods
Ethics statement. Experiments involving live animals were conducted in accor-
dance with the European guidelines and the Belgian legislation on animal housing
and experimentation, and were approved by the Ethical Committees of Animal
Experimentation of the Vrije Universiteit Brussel (Permit nos. EC15-272-7 and
EC16-334-1) and by the Ethical Committee of the Faculty of Veterinary Sciences of
Ghent University (Permit no. EC2015/26).
Choice and synthesis of toxins and AMPs. Three toxin–AMP pairs were selected
as models for this study, each representing cosecreted peptides from different clade
of frogs: (1) the toxin caerulein (Cae) and the AMP caerulein precursor factor-3
(CPF) from the skin of the African clawed frog X. laevis (Pipidae); (2) the toxin
bombesin (Bom) and the AMP BLP from the skin of the oriental ﬁre-bellied toad B.
orientalis (Discoglossoidea: Bombinatoridae); and (3) the toxin dermorphin (Drm)
and the AMP dermaseptin-S1 (Drs) from the skin of the waxy tree frog P. sauvagii
(Neobatrachia: Hylidae). Sequences and molecular weights of these peptides are
provided in the appropriate ﬁgures (Figs. 1 and 3). The toxins were selected
based on their well-documented systemic effects in vertebrates9,10,31 and on the
commercial availability of ELISA kits to allow their in vitro quantiﬁcation (see
below). The selected AMPs show broad-spectrum antimicrobial activity as
conﬁrmed by previous studies18,52,53 and are considered part of the frogs’ innate
immune system3,14–18. All peptides were synthesized via standard Fmoc-based
solid-phase peptide synthesis by the authors and by CASLO Laboratory ApS
(Lyngby, Denmark). For radiolabeling, a caerulein analog, modiﬁed with a
diethylenetriaminepentaacetic acid (CHX-A″-DTPA) at the N-terminal side of
the peptide (i.e., CHX-A″-DTPA-βAla-Pro-Gln-Asp-Tyr-Thr-Gly-Trp-Met-Asp-
Phe-NH2), as a chelator for the isotope indium-111 (Supplementary Fig. 2), was
synthesized. Resin-bound peptide (Fmoc-βAla-Pro-Gln(Trt)-Asp(OtBu)-Tyr
(OtBu)-Thr(OtBu)-Gly-Trp(Boc)-Met-Asp(OtBu)-Phe-Rink Amide resin) was
synthesized manually and after Fmoc deprotection of the N-terminal β-Ala residue,
a solution of CHX-A″-DTPA•3HCl (1.4 eq.) and DIPEA (9 eq) in dichlor-
omethane (DCM)/dimethylformamide (DMF) (2:1, v/v) was added to the resin-
bound peptide and the reaction mixture was stirred at room temperature for 16 h.
The resin was washed subsequently with DMF, 2-propanol, and DCM. The
complete conversion was veriﬁed by Kaiser test, as well as by high-performance
liquid chromatography (HPLC) analysis. The cleavage of the peptides from the
resin and the removal of acid-labile protecting groups were achieved using a
mixture of TFA/TES/H2O (95:2.5:2.5, v/v) for 3 h. After evaporation of the clea-
vage mixture and precipitation in cold Et2O, the crude peptides were puriﬁed by
semi-preparative reverse phase-HPLC using a mixture of CH3CN/H2O, containing
1% triﬂuoroacetic acid (TFA), as mobile phase. The peptides were delivered as
HPLC-puriﬁed (> 95%) TFA salts. The caerulein-modiﬁed peptide containing
(CHX-A″-DTPA) was isolated with 7% yield. Most peptide salts were dissolved in
Milli-Q water to obtain 10 mM peptide stock solutions for storage at 4 °C.
Cell culturing. Two models of gastrointestinal epithelia were selected to represent
the mucosal barrier that toxins must cross in order to enter the basolateral tissue
and blood of a predator. The Caco-2 cell line (Human cancerous intestinal cells,
authenticated using light microscopy) was chosen because of its wide application in
in vitro epithelial drug transport studies. EpiOral 3D tissues (ordered from Mattek
TM, USA) were selected to test toxin transport across a more complex epithelial
model composed of 8–11 cell layers. Caco-2 cells were cultured in cell medium
(87% Dulbecco’s modiﬁed Eagle’s medium nutrient mix, 10% fetal calf serum,
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1% non-essential amino acid, 1% kanamycin, 1% penicillin–streptomycin, and
0.1% amphotericin B) in a humidiﬁed incubator (90% humidity, 5% CO2) at a
constant temperature of 37 °C. To prepare an experiment, cultured cells were
seeded on the appropriate inserts/wells/coverslips 21 days in advance, at a con-
centration of 2×105 cells/ml and further cultured to develop conﬂuent and fully
differentiated monolayers (composed cells with polarized apical and basolateral
membranes and cell-cell adhesion complexes). The progress of conﬂuence and
differentiation was checked by light microscopy and measuring electrical resistance
across the cell layer, respectively.
LDH leakage assays. Cell-damaging activity of the peptides was tested using
commercial LDH II assay kits (Abcam, USA) and Caco-2 cell cultures prepared in
96-well plates (see above), with each well containing 200 µl of medium. For each
toxin–AMP pair (see above), cell cultures were exposed for 5 min to three different
AMP + toxin concentrations (100, 50, and 25 µM) and a single toxin concentration
(100 µM). Additionally, we tested the effect of only administering the AMPs at the
same three concentrations. Nine wells containing cells and medium but no peptide
served as negative controls (representing background LDH release in the absence of
cell damage, or “0% LDH leakage”). Six wells containing 1% triton-X lysis solution
were used as positive controls (representing the LDH release caused by 100% cell
lysis, or “100% LDH leakage”). After completing the colorimetric reaction
according to the kit’s manual, optical density (OD) was measured at 450 nm using
a multiskan FC microplate photometer/ELISA reader (Thermo Scientiﬁc). The cell-
damaging effect of a peptide (in % LDH leakage) was calculated as: 100 × (ODX −
ODN)/(ODP −ODN), where ODX is the corrected OD value of sample x, ODN is
the average corrected OD obtained for the nine negative control wells, and ODP is
the average corrected OD obtained for the six positive control wells. Note that the
resulting % LDH leakage can be higher than 100%, e.g., if a peptide does not lyse all
cells (unlike the total cell lysis in our positive control), leaving the surviving and
damaged cells to continue to produce and release additional LDH. Consequently,
our LDH leakage assays should be regarded as measures of cell membrane damage,
not cell death.
Monitoring of epithelial permeability. The effect of peptide administration on
epithelial permeability was investigated by monitoring TEER on Caco-2 cell
monolayer cultures. For each toxin–AMP pair (see above), ﬁve treatments (n = 9)
were monitored: (1) apical administration of the toxin alone, at 100 μM; (2) apical
administration of toxin + AMP, both at 100 μM; (3) toxin + AMP, both at 50 μM;
(4) toxin + AMP, both at 25 μM; and (5) no peptide administration (negative
control). Caco-2 cells were prepared (see above) on collagen-coated polystyrene
transwell insert ﬁlters with a 0.4 µm pore size (Corning Life Sciences, USA). Inserts
were placed in 24-well plates (provided with the inserts), creating an apical com-
partment (the insert) and a basolateral compartment (the well). Monitoring of
TEER was done using a STX2 “Chopstick” electrode connected to an EVOM
voltohmmeter (World Precision Instruments Inc). The original TEER (TEERO;
corresponding 100% epithelial integrity), was measured 30 min before adminis-
tration of the peptides. Peptides were administrated by replacing the apical med-
ium by fresh medium in which the peptides were dissolved. As frequent exposure
to electrical currents can damage epithelial cells (explaining the shallow drop of
TEER at time 0 in the negative controls in Figs. 1d and 3d), an incubation time of
minimum 30 min between successive TEER measurements was respected. Hence,
TEER was measured 5 min after peptide administration and then at 30-min
intervals until 3 h after administration, and at 60-min intervals until 6 h after
administration. A ﬁnal measurement was taken at 24 h after peptide administration
to monitor recovery of the monolayers after the peptide treatment (data not
shown). Relative TEER (in %) values were calculated as 100 × TEERX/TEERO,
where TEERX is the measured TEER at time X.
Scanning electron microscopy imaging. Caco-2 cells were seeded on glass cov-
erslips that were coated with rat tail collagen 1 (Sigma-Aldrich) the day before. The
effect of four treatments (100 µM CPF, 100 µM caerulein, 100 µM CPF + caerulein,
and a negative control) on differentiated Caco-2 monolayers was visualized.
Chemical ﬁxation was performed in 12-well culture plates 5 min after peptide
administration (700 µl of solution in all treatments). For ﬁxation, plate wells were
ﬁlled with 1 ml 2,5% glutaraldehyde in 0.05M sodium cacodylate buffer (pH 7.4;
37 °C) for 20 min, and subsequently washed twice with the same buffer. Postﬁxa-
tion was performed with 1% osmium tetroxide for 30 min, followed by three rinses
with double-distilled water. Dehydration was carried out using a graded hexylene
glycol series: 30; 50; 70; and 90%, taking 15 min for each step. Cells were rinsed
three times for 10 min with 100% hexylene glycol, and then two more times for
10 min with 100% ethanol. Critical-point drying of coverslips was done using a
Balzers union CPD020. Dried coverslips were mounted on carbon-coated stubs
with double-sided conductive tape. Gold coating happened with a Jeol 1200JFC ﬁne
coater, after which coverslips were examined with a Jeol JSM-840 scanning electron
microscope operating at 12 kV.
Quantiﬁcation of transepithelial toxin passage. Toxin concentrations were
quantiﬁed by ELISA using commercially available kits that show 100% cross-
reactivity with the toxin in question. Caerulein was quantiﬁed using the
Cholecystokinin Octapeptide (CCK) (26-33) (non-sulfated) ELISA kit (Phoenix
Pharmaceuticals Inc., Burlingame, USA), bombesin was quantiﬁed using the
Bombesin ELISA kit (Peninsula Laboratories International Inc.), and dermorphin
was quantiﬁed using the MaxSignal Dermorphin ELISA kit (Biooscientiﬁc.com).
For each toxin–AMP pair, AMP-induced increase in the passage of the toxin across
Caco-2 monolayers was investigated by comparing basolateral concentrations at
60 min after apical administration of either 20 nmol of the toxin alone (yielding a
concentration of 100 µM; n= 9), or after apical administration of 20 nmol toxin +
20 nmol AMP (100 μM for both; n= 9). Toxin passage across EpiOral multilayered
cell cultures was investigated for the caerulein–CPF pair in a similar setup (n= 8).
Each basolateral sample was stepwise diluted in cell medium and transferred to an
ELISA kit plate. Six wells containing negative control samples (only cell medium)
and two wells containing positive control samples (supplied with the kits) were
added. Assays were performed following the standard protocols provided with the
kits’ manuals. Standard curves for each toxin were obtained in duplicate. OD was
measured at a wavelength of 450 nm using a multiskan FC microplate photometer/
ELISA reader (Thermo Scientiﬁc). OD values were converted into toxin con-
centrations using the four-parameter curve ﬁtting software (Masterplex, MiraiBio
Group, Hitachi Solutions America Ltd and elisa-analysis.com).
Quantiﬁcation of peptides in skin secretion. Previous studies have estimated that
AMP concentrations in the skin secretion of various frog species are in the mil-
limolar range26–28. For X. laevis, AMP concentration estimates range between 4.5
and 19.6 mg/ml, and CPF seems one of the most abundant peptides18–20. Using
CPF as a proxy for all X. laevis AMPs, and given its molecular weight of 2602 Da,
these observations would correspond to a CPF concentration of ~1.8–7.8 mM. The
lower limit of this range is slightly above the concentration used in part of our
in vivo experiments (see below). Caerulein concentrations in X. laevis skin secre-
tions were estimated using ELISA. Adult female X. laevis frogs (n= 8) were ordered
from a licensed commercial breeder (Xenopus Express France) and housed in
plastic containers of 70 × 45 × 45 cm (L×B×H), ﬁlled with 25 cm of aged tap water
with a ﬁltration system, and kept in a acclimatized animalarium with a 12/12-h
day-and-night cycle. To collect skin secretion, each frog was placed in a plastic
ziplock bag and manually massaged to simulate the swallowing motion and eso-
phageal peristalsis of a predator (as expected during an attack). The secretion
produced during this stimulation tends to stick to the inner surface of the bag and
is therefore easy to collect. After 5 min, all secretion on the frog and the bag’s inner
surface was collected in a pre-weighed 1.5 ml microcentrifuge tube using a spatula,
brieﬂy centrifuged at 10,000 r.p.m. and weighed again to obtain a net weight for the
skin secretion. Obtained skin secretion samples ranged between 85.7 and 419.8 mg,
roughly corresponding to 85–420 μl. The secretion samples were subsequently
diluted to obtain 10 ml of a 9 M urea/0.1% TFA solution, and fully dissolved by
brief vortexing. A 100 μl sample of each solution was used to measure caerulein
amounts and concentrations via the ELISA procedure described above. Using the
ELISA results, we inferred that the individual frogs produced between 0.12 and
4.27 mg caerulein, amounts that are high, but comparable to those estimated for
several peptide toxins in other frogs10,39,40. Combined with the estimated skin
secretion volumes, the estimated amounts correspond to skin secretion con-
centrations between 1.0 and 7.5 mM, and the lowest limit of this range was used as
a biologically realistic concentration for in vivo experiments (see below).
In vivo quantiﬁcation of absorbed radiolabeled caerulein. To investigate toxin
absorption in a live model predator, radiolabeled caerulein was quantiﬁed in the
blood and organs of snakes of the species Thamnophis eques (Colubridae: Natri-
cinae) after oral administration in the presence vs. absence of CPF. Adult female
snakes of this species (n = 18) were purchased from J & M Garters (Spijkenisse,
The Netherlands), and housed in 70 × 40 × 20 cm plastic boxes (L×B×H), kept in a
acclimatized animalarium with a 12/12-h day-and-night cycle at 20–25 °C. A ﬁrst
experiment was designed to test a biologically realistic peptide concentration, and
involved a comparison of two treatments (n= 3): (1) oral administration of 50 µl
buffer solution, containing 50 nmol caerulein + 50 nmol CPF (i.e., both at 1 mM);
and (2) oral administration of 50 µl buffer solution containing 50 nmol (1 mM)
caerulein alone. A sample size of three was chosen because it allows for sufﬁcient
statistical power using linear mixed modeling (see below) at a minimum cost of
animal lives. A second experiment was designed to test a peptide concentration
corresponding to our in vitro tests, which involved the following two treatments (n
= 6): (1) oral administration of 50 µl buffer solution containing 5 nmol caerulein +
5 nmol CPF (i.e., both at 100 μM); and (2) oral administration of 50 µl buffer
solution containing 5 nmol (100 µM) caerulein alone. Here a sample size of six was
chosen because we suspected a lower effect size than in the previous experiment
due to the lower peptide concentrations.
For each experiment, snakes were selected for both treatments to obtain
identical distributions of BWs. Caerulein-DTPA (65 or 375 nmol) was labeled with
111InCl3 (65–90MBq) (Mallinckrodt Pharmaceuticals) in 0.2 M NH4OAc (pH
5.0; ammonium acetate) by incubation at 50 °C for 30 min (total volume 413 µl).
Radiochemical purity (>95%) was veriﬁed by iTLC on silica gel (Pall Corporation)
using 0.1 M sodium citrate buffer (pH 5.0) as mobile phase. Snakes were
anesthetized with an intracardial injection of propofol (12 µg/g BW) and
subsequently positioned on their back. Peptide solutions were orally administered
with standard syringes by carefully dripping the content (50 µl of a 1 mM or 100
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01710-1
6 NATURE COMMUNICATIONS |8:  1495 |DOI: 10.1038/s41467-017-01710-1 |www.nature.com/naturecommunications
µM buffer solution) on the palate of the snakes, after which the remaining
radioactivity of the syringe was measured to determine the radioactivity of actual
administered oral dose. Blood samples (10–50 µl) were taken from the heart with
standard insulin syringes at predetermined time points after the start of the
experiment (deﬁned as the moment of oral peptide administration). After 30 min,
snakes were euthanized with an intracardial injection of T61 (0.5 µg/g BW) and
organs and tissues were collected and weighed. Organ and tissue radioactivity was
measured in a gamma counter against a standard of known activity and corrected
for the decay in radioactivity. The investigator conducting these measurements was
blinded to the oral administration treatments (presence vs. absence of CPF). Before
the onset of the experiment, it was decided that samples would be excluded from
the analysis only if radioactive contamination during the dissection was deemed
highly probable. This was the case for one measurement for the brain (one snake
treated with 1 mM caerulein + CPF), where radioactive contamination from the
oral cavity during excision of the brain from the skull could not be ruled out.
Caerulein levels in the snakes’ blood and organs were expressed in pmol/gram
(blood or tissue). Unlike experiments based on intravenous injection, it is
impossible to infer absolute absorption efﬁciencies based on the total amount of
toxin in a subject’s body at any time after oral administration. Yet, to allow
comparison with doses based on whole BWs, as reported in previous studies on
caerulein toxicity, the obtained blood values were corrected for the proportion of
blood in a snake’s body (5–8%)29, yielding values in pmol/gram BW. Note that
these values may represent an increasingly larger underestimation of the actual
amount of toxin absorbed by a snake’s body, since an increasingly large fraction of
the orally administered dose will have been transferred from the blood to other
tissues. As an additional measure for systemic toxin exposure, we calculated for
each snake the AUC value (expressed in pmol×min/g). The AUC value
incorporates multiple successive measurements of the amount of toxin in the
blood, and is calculated as the area under the connecting lines between successive
data points as deﬁned by the commonly used “trapezoidal rule” method54–56.
Statistics. All data series were tested for normality and equality of variance and
subsequently analyzed using SPSS version 23.0 (IBM Corp, USA; most tests) and R
version 3.1.1 (https://www.r-project.org; linear mixed models). Differences in
TEER among peptide treatments were evaluated using one-way analysis of variance
with a Tukey (equal variances assumed) or Games–Howell (equal variances not
assumed) post hoc test. Pairwise differences in transepithelial toxin passage
between treatments (ELISA) were evaluated using Student’s t-tests. Linear mixed
models considering “time” and “treatment” (different peptide administrations) as
ﬁxed factors and “snake individual” as random factor were used to test for dif-
ferences in caerulein blood levels over time between treatments. Linear mixed
models considering “organ” and “treatment” as ﬁxed factors and “snake individual”
as random factor were used to evaluate their effects on caerulein levels in organs
and blood after 30 min.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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